Wyngaarden To Step Down As NIH Director

WASHINGTON—The resignation of James Wyngaarden last month after more than seven years as director of the National Institutes of Health may have caught scientists by surprise. But it was a long time coming for the 64-year-old Wyngaarden. In fact, his last day on the job, July 31, will be nine months past the date when the soft-spoken former Duke University medical schcol administrator had hoped to leave the post. It’s clear that Wyngaarden has had his fill of the political battles

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON—The resignation of James Wyngaarden last month after more than seven years as director of the National Institutes of Health may have caught scientists by surprise. But it was a long time coming for the 64-year-old Wyngaarden. In fact, his last day on the job, July 31, will be nine months past the date when the soft-spoken former Duke University medical schcol administrator had hoped to leave the post.

It’s clear that Wyngaarden has had his fill of the political battles that go with his position. Speaking candidly about the Reagan years, he admits that “we’ve had no consistent science policy” for that entire period. He describes the annual budget process as a situation where “the administration tries to get by with as little as it can, and then Congress repairs the damage to the greatest extent possible.”

That constant struggle for funds can be exhausting, Wyngaarden admits. “Last year ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies